All In Biotech

Drug Trial Radar · NCT06500702

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Dec 19, 2024

Primary completion

Dec 23, 2026

Study completion Feb 16, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years. Study details for each participant include: The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.

Conditions

  • Focal Segmental Glomerulosclerosis
  • Glomerulonephritis Minimal Lesion

Interventions

  • frexalimabDrug

    frexalimab treatment

  • brivekimigDrug

    brivekimig treatment

  • rilzabrutinibDrug

    rilzabrutinib treatment

  • placeboDrug

    placebo treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent reduction in urine protein to creatinine ratio (UPCR)Time frame: From baseline to Week 12

Locations

82 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama -The Kirklin Clinic- Site Number : 8400007

    Birmingham, Alabama · Recruiting

  • University of California Irvine Medical Center- Site Number : 8400015

    Orange, California · Recruiting

  • University of California San Francisco - Parnassus Heights- Site Number : 8400012

    San Francisco, California · Recruiting

  • University Of South Florida - Parent- Site Number : 8400025

    Tampa, Florida · Recruiting

  • Emory Children's Center- Site Number : 8400020

    Atlanta, Georgia · Recruiting

  • Northwestern Memorial Hospital- Site Number : 8400014

    Chicago, Illinois · Recruiting

  • Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale- Site Number : 8400017

    Hinsdale, Illinois · Recruiting

  • University of Michigan Health System - Ann Arbor- Site Number : 8400010

    Ann Arbor, Michigan · Recruiting

  • InterMed Consultants - Edina Clinic- Site Number : 8400019

    Edina, Minnesota · Recruiting

  • DaVita Clinical Research - Las Vegas - North Rainbow Boulevard- Site Number : 8400018

    Las Vegas, Nevada · Active not recruiting

  • Renal Medicine Associates- Site Number : 8400028

    Albuquerque, New Mexico · Recruiting

  • Columbia University Irving Medical Center- Site Number : 8400001

    New York, New York · Recruiting

  • The Children's Hospital at Montefiore- Site Number : 8400027

    The Bronx, New York · Recruiting

  • UNC Kidney Center- Site Number : 8400021

    Chapel Hill, North Carolina · Recruiting

  • Cleveland Clinic - Cleveland- Site Number : 8400029

    Cleveland, Ohio · Recruiting

  • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400024

    Dallas, Texas · Recruiting

  • El Paso Kidney Specialists- Site Number : 8400005

    El Paso, Texas · Recruiting

  • Prolato Clinical Research Center- Site Number : 8400016

    Houston, Texas · Recruiting

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320002

    Córdoba, Argentina · Recruiting

  • Investigational Site Number : 0360003

    Garran, Australian Capital Territory, Australia · Recruiting

  • Investigational Site Number : 0360001

    Parkville, Victoria, Australia · Recruiting

  • Hospital do Rim e Hipertensão- Site Number : 0760002

    São Paulo, Brazil · Recruiting

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001

    São Paulo, Brazil · Recruiting

  • Universidade Estadual Paulista - Faculdade de Medicina de Botucatu- Site Number : 0760004

    Botucatu, São Paulo, Brazil · Recruiting

  • Synvia Clinical- Site Number : 0760005

    São Paulo, São Paulo, Brazil · Recruiting

  • Investigational Site Number : 1240002

    London, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240004

    Toronto, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240001

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 1240005

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 1240006

    Québec, Quebec, Canada · Recruiting

  • Investigational Site Number : 1520003

    Temuco, La Araucanía, Chile · Recruiting

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1560001

    Beijing, China · Recruiting

  • Investigational Site Number : 1560003

    Chengdu, China · Recruiting

  • Investigational Site Number : 1560004

    Shanghai, China · Completed

  • Investigational Site Number : 2030002

    Olomouc, Czechia · Recruiting

  • Investigational Site Number : 2030001

    Prague, Czechia · Recruiting

  • Investigational Site Number : 2500002

    Créteil, France · Recruiting

  • Investigational Site Number : 2500001

    Paris, France · Recruiting

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.